SEC 13F Intelligence

Managers / Q1 2019 · view latest →

VHCP Management II, LLC

CIK 0001602263 · 7 BRYANT PARK, 23RD FLOOR, NEW YORK, NY, 10018 · 650 475 3734

Reported Value
$342M
Q1 2019
Positions
21
Filings on Record
4
2019–present window
Filed
May 14, 2019
original filing

Summary

Vhcp Management II, LLC reported $342M in U.S.-listed holdings across 21 positions for Q1 2019.

Its largest position, ASND, represents 17.4% of the portfolio.

Portfolio Metrics

Top-10 Concentration
+88.5%
share of reported value
Largest Position
+17.4%
Ascendis Pharma A S

Methodology: turnover is min(value bought, value sold) ÷ average reported value across the two quarters — value-based, so market moves inflate it slightly versus a share-based measure. Concentration and largest position are shares of the filing’s total reported value, options excluded, with multiple share classes and repeated sub-manager rows for the same issuer combined into one position — the same rule the holdings table uses by default. New/exited counts compare against the prior filed quarter. All figures derive solely from the fund’s 13F filings.

Reported Value by Quarter

13F Reported Value
Q1 ’19: $342MQ1 ’19Q2 ’19: $317MQ2 ’19Q3 ’19: $262MQ3 ’19Q4 ’19: $379MQ4 ’19filingsflow.com

Portfolio Composition

By security type
Common Stock: 70.8%Other: 29.1%ADR: 0.1%
  • Common Stock · 70.8% · $242M
  • Other · 29.1% · $100M
  • ADR · 0.1% · $221,000

Quarter-over-Quarter Changes full breakdown →

IssuerMoveShare ΔShares nowValue ΔValue now
ASNDAscendis Pharma A/SNEW+504.2K504.2K+$59M$59M
Biohaven PharmaceuticalsNEW+1.14M1.14M+$59M$59M
Tricida IncNEW+962.7K962.7K+$37M$37M
Shockwave Medical IncNEW+901.3K901.3K+$30M$30M
Obseva SANEW+2.25M2.25M+$29M$29M
BCRXBioCryst Pharmaceuticals IncNEW+3.25M3.25M+$26M$26M
ZogenixNEW+362.0K362.0K+$20M$20M
Kalvista PharmaceuticalsNEW+573.5K573.5K+$16M$16M

Value changes conflate price moves with buying and selling — share changes are the real signal. Share counts are not split-adjusted.

Holdings — Q1 2019

21 positions
Export to Excel
#IssuerClass% PortfolioValue ↓Shares
1ASNDAscendis Pharma A/Shistory →COM17.37%$59M504.2K
2Biohaven PharmaceuticalsCOM17.14%$59M1.14M
3Tricida IncCOM10.88%$37M962.7K
4Shockwave Medical IncCOM8.83%$30M901.3K
5Obseva SACOM8.43%$29M2.25M
6BCRXBioCryst Pharmaceuticals Inchistory →COM7.74%$26M3.25M
7ZogenixCOM5.83%$20M362.0K
8Kalvista PharmaceuticalsCOM4.80%$16M573.5K
9Ra PharmaceuticalsCOM4.15%$14M632.5K
10Kiniksa Pharmaceuticals LtdCOM3.38%$12M639.2K
11CNSTConstellation Pharmaceuticalshistory →COM2.88%$10M726.7K
12AXSMAxsome Therapeutics Inchistory →COM2.38%$8M572.0K
13SPROSpero Therapeutics Inchistory →COM1.78%$6M474.0K
14PTGXProtagonist Therapeutics IncCOM1.00%$3M271.4K
15Marinus Pharmaceuticals IncCOM0.91%$3M743.9K
16Bellerophon TherapeuticsCOM0.79%$3M4.15M
17LJPCLa Jolla PharmaceuticalsCOM0.70%$2M371.4K
18KDMNKadmon Holdings Inc.COM0.63%$2M820.1K
19Gemphire TherapeuticsCOM0.17%$591,000513.8K
20Proteostasis Therapeutics IncCOM0.16%$538,000427.1K
21Orchard RX LtdCOM0.06%$221,00012.4K

Filing History

QuarterReported ValuePositionsFiledTypeLinks
Q4 2019$379M20Feb 13, 202013F-HRchanges · EDGAR ↗
Q3 2019$262M21Nov 13, 201913F-HRchanges · EDGAR ↗
Q2 2019$317M21Aug 13, 201913F-HRchanges · EDGAR ↗
Q1 2019$342M21May 14, 201913F-HRchanges · EDGAR ↗

13F filings are due up to 45 days after quarter end, so holdings shown here lag the fund’s current book. Source: original SEC filing on EDGAR ↗.